Portuguese 
English 
Spanish 
5 min of reading 
0 comments 
The new law 15.385/26, sanctioned without vetoes, determines that therapeutic vaccines against cancer have priority in the SUS, with free access to medications, diagnostic tests, and advanced therapies. The legislation also provides incentives for national biotechnology production and the use of artificial intelligence in oncological research.
A new law sanctioned by President Luiz Inácio Lula da Silva has just placed the cancer vaccine at the center of Brazil’s public health policies. Published in the Official Gazette of the Union this Monday (13), Law 15.385/26 determines that therapeutic vaccines and other innovative treatments have priority access in the Unified Health System. The new law was approved by the National Congress without vetoes and creates guidelines to accelerate the incorporation of technologies in the fight against cancer, facilitating free access to medications, diagnostic tests, and advanced therapies for patients in the public network.
What makes this legislation particularly relevant is the type of vaccine it prioritizes. Unlike traditional vaccines that prevent diseases, cancer vaccines are therapeutic and personalized: they are developed from the genetic analysis of each patient’s tumor, stimulating the immune system to recognize and attack cancer cells specifically. “This type of vaccine offers the human body a greater capacity to recognize and combat specific tumors, representing a new era in oncological treatments,” explains oncologist Breno Jeha Araújo, a clinical genomics specialist at Oncoclínicas. The new law ensures that this technology reaches the SUS with priority processing.
What the new law changes in practice for cancer patients in the SUS
The main change introduced by the new law is the creation of an accelerated pathway for innovative oncological vaccines and treatments to be evaluated and incorporated into the SUS. Before this legislation, the process of approval and release of new health technologies followed a standard procedure that could take years between scientific validation and actual availability for patients in the public network. With Law 15.385/26, cancer treatments will have priority processing, respecting the rules of regulatory agencies.
-
Children who care for elderly parents can now receive more than 800 reais per month in Paraná with the Bolsa Cuidador program, which is already operating in 20 cities and may expand to more municipalities.
-
The profession that teaches machines to predict future sales pays R$ 14,000 at the mid-level and over R$ 22,000 at the senior level, and its value has increased by 40% in just two years in Brazil.
-
Brazil exported tons of rare earth mining to Canada last week and is targeting the United States and China to sell critical minerals used in permanent magnets, electronics, electric vehicles, wind turbines, nuclear energy, and defense.
-
Understand how Manaus generates R$ 227 billion and redefines the economy of the North with job creation, industrial advancement, and new strategic investments that support consistent regional growth with the Free Trade Zone.
In practice, this means that cancer patients treated by the SUS will have faster access to therapeutic vaccines, next-generation medications, and advanced diagnostic tests. The new law also establishes criteria based on each patient’s clinical and immunological profile, which opens up space for personalized treatments within the public network, something that until now was restricted to private clinics and reference hospitals. The free provision of these treatments is guaranteed by the legislation, eliminating the financial barrier that prevented millions of Brazilians from accessing cutting-edge therapies.
How the cancer vaccines prioritized by the new law work
According to the portal ndmais, the cancer vaccines that the new law prioritizes in the SUS do not work like traditional vaccines. While conventional vaccines prevent infections by training the immune system against viruses or bacteria, therapeutic cancer vaccines are designed to treat existing tumors. The process begins with the genetic analysis of the patient’s tumor, which identifies the specific mutations of cancer cells. Based on this information, the vaccine is custom-developed.
Once administered, the vaccine teaches the immune system to recognize these mutations as targets, triggering a targeted immune response that attacks tumor cells without destroying healthy tissues. This level of precision represents a significant advancement over conventional treatments like chemotherapy, which affects both sick and healthy cells. The new law recognizes the transformative potential of this technology and creates the conditions for it to be available free of charge in the Brazilian public health system.
The incentives for national biotechnology production provided for in the new law
In addition to accelerating access to treatments, the new law has a strategic component aimed at Brazil’s technological independence in the health sector. The text provides for incentives for the national development of oncological technologies, including funding through the National Fund for Scientific and Technological Development, support for biotechnology startups, and partnerships between the public and private sectors.
The new law also provides for the use of artificial intelligence in oncological research, a technology that can accelerate the identification of therapeutic targets and reduce the time for developing new vaccines. The declared goal is to reduce dependence on imports of medications and health technologies, a chronic problem of the Brazilian public system that raises treatment costs and limits the population’s access to cutting-edge therapies. If the incentives provided by the new law are effectively implemented, Brazil could become a hub for cancer vaccine production in Latin America.
What still needs to happen for the new law to work in practice
Sanctioning the new law is the first step, but the distance between publication in the Official Gazette and the actual availability of cancer vaccines in the SUS can be long. The regulation of the law will require agencies such as Anvisa and Conitec to define the protocols for accelerated evaluation, the eligibility criteria for patients, and the mechanisms for acquiring and distributing vaccines through the public network. Without this regulation, the new law remains a statement of intentions.
Another challenge is cost. Personalized cancer vaccines are, by definition, more expensive than standardized treatments, and the SUS budget will need to absorb this demand without compromising other health programs. The new law provides for specific funding sources, but budget execution will depend on political decisions in the coming years. For the more than 200 million Brazilians who depend on the SUS, the legislation represents a concrete hope, as long as the implementation matches the ambition of the approved text.
What the new law means for the future of cancer treatment in Brazil
Law 15.385/26 places Brazil among the countries that formally recognize therapeutic vaccines against cancer as a public health priority. The new law does not invent the technology nor guarantee its efficacy, but creates the legal framework for scientific advances to reach SUS patients in a timeframe compatible with the urgency that a cancer diagnosis imposes. Awareness campaigns about prevention and treatment are also planned, extending the reach of the legislation beyond treatment centers.
Cancer is the second leading cause of death in Brazil, and the inequality in access to treatments between the public and private networks is historical. The new law addresses this problem at its root by ensuring that cutting-edge technologies are not a privilege for those who can pay, but a right for those who need it. If the implementation is successful, the country will have taken a step that could transform how millions of Brazilians face the disease. The text of the law is approved. Now the work begins to turn it into real treatment.
The new law prioritizes the cancer vaccine in the SUS and guarantees free access to personalized treatments. Do you think Brazil will be able to implement this technology in the public network? Is the SUS prepared?
Seja o primeiro a reagir!